Sydney - Novotech, a leading biotech specialist CRO in the Asia-Pacific region, is sponsoring the ChinaTrials13 conference and will have teams from Novotech’s China offices attending to support biotechs planning clinical trials in China and the Asia-Pacific region (11-21, November 2021).
The conference brings together China biotechs as well as regional and international firms looking to expedite quality trials.
Of particular focus is oncology research. According to GlobalData, China has the highest incidence of cancer in the world, accounting for 24% of newly diagnosed cases and 30% of cancer-related deaths worldwide in 2020.
Meet the Novotech team at Booth: #11&12
Presentations by Novotech
Workshop: Navigating the Future of Cell Therapies Development: Unlocking the Full Potential
10th November, 9am – 12pm
Topics include:
- CAR-T Therapy: Key considerations during clinical development
- Execution and quality management for cell therapy clinical development
- Statistical considerations in CAR-T therapy clinical trials
Key Novotech experts along with industry leaders will present, then open up for discussions around key issues.
Some of the topics covered at the conference include:
- The Next Phase of Chinese Innovative Biotech Drug Development
- China+US Development: Should You File Your IND in the US Before/After or Simultaneously Alongside Your China IND?
- China CMO Roundtable: What's On the Minds of China's Top CMO's?
- Decentralized Clinical Studies: How COVID-19 Changed Clinical Development & Lessons Learned
- Regulatory Insights: Taking Advantage of Fast Track Channels
- MNC Perspectives: China's New Role in Global Development
- Global Drug Development 2.0: Borderless Innovation
- Cell & Gene Therapy Drug Development in China: What's Next?
- Experience Sharing: China Biotech + MNC Pharma Drug Development Partnerships
- Digital Technology to Support Remote Inspection to Accelerate Clinical Research: PI, Site and Sponsor Perspectives
- Choosing the Right Clinical Development Strategy to Optimize Regulatory Approval Pathway
- Win From the Start: Early Clinical Research Strategies for Innovative Drugs
- Strategy & Planning of Innovative Drugs in MRCT
- How to Design Trials to Better Serve the Needs of Clinical & Needs of Patients
- Strategies for Moving Quickly from Phase I to Phase II
- Seamless Global Development from Phase I to III: A Tale of COVID-19 Antibody Cocktail Therapy
- Real World Data: The Road to Bringing Innovative Therapies to Patients Faster?
媒體聯絡人
Toyna Chin
關於Novotech Novotech-CRO.com
Novotech作為一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司,深受生物科技公司以及中小型製藥公司的信賴,引領其在各個階段的藥物開發。
公司在全球各地擁有30多個辦公據點,主要分佈在亞太地區、北美和歐洲,並與5000多個試驗機構建立了緊密的合作關係,為客戶提供豐富的臨床試驗資源網絡,幫助客戶輕鬆進軍關鍵試驗區域,廣泛接觸不同的受試者群體,推動變革性療法更快嘉惠患者。
透過以客戶為中心的服務模式,Novotech無縫整合人才、流程和技術,提供定制化解決方案,加速變革療法快速上市。透過建立緊密的合作夥伴關係,Novotech堅定不移地支援客戶實現研究目標,賦能創新,推動全球醫療健康發展。憑藉在臨床試驗執行和創新方面的卓越表現,Novotech已榮獲多項殊榮,包括連續19年蟬聯Frost & Sullivan CRO年度公司獎 (Frost & Sullivan CRO Company of the Year)。憑藉深厚的臨床領域與監管專業知識,再結合對當地市場的深刻洞察,公司致力於簡化臨床試驗流程,提升資料分析,並加快受試者招募策略的實施。
Novotech與客戶攜手並進,加速科學研發成果轉化為療法,改善全球患者結果,充分體現我們推動創新、實現卓越成果的使命。
如需瞭解更多資訊或與專家團隊成員洽談,請造訪www.Novotech-CRO.com